ACADIA Pharmaceuticals Inc Asset Resilience Ratio
ACADIA Pharmaceuticals Inc asset resilience ratio. ACADIA Pharmaceuticals Inc (ACAD) has an Asset Resilience Ratio of 32.79% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ACAD defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ACADIA Pharmaceuticals Inc (2002–2025)
Asset resilience ratio of ACADIA Pharmaceuticals Inc from 2002 to 2025. This chart shows how ACADIA Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read ACADIA Pharmaceuticals Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ACADIA Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ACAD total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $571.49 Million | 32.79% |
| Total Liquid Assets | $571.49 Million | 32.79% |
Asset Resilience Insights
- Very High Liquidity: ACADIA Pharmaceuticals Inc maintains exceptional liquid asset reserves at 32.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ACADIA Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare ACADIA Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
ACADIA Pharmaceuticals Inc Asset Resilience Ratio by Year (2002–2025)
ACADIA Pharmaceuticals Inc asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for ACADIA Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.04% | $641.99 Million | $1.56 Billion | +4.30pp |
| 2024-12-31 | 36.74% | $436.40 Million | $1.19 Billion | +3.33pp |
| 2023-12-31 | 33.41% | $250.21 Million | $748.96 Million | -17.97pp |
| 2022-12-31 | 51.37% | $301.98 Million | $587.81 Million | -1.94pp |
| 2021-12-31 | 53.32% | $373.27 Million | $700.12 Million | +14.22pp |
| 2020-12-31 | 39.09% | $305.93 Million | $782.62 Million | -25.74pp |
| 2019-12-31 | 64.83% | $507.75 Million | $783.18 Million | +2.12pp |
| 2018-12-31 | 62.71% | $338.76 Million | $540.20 Million | -8.01pp |
| 2017-12-31 | 70.72% | $271.92 Million | $384.51 Million | +5.60pp |
| 2016-12-31 | 65.12% | $365.42 Million | $561.15 Million | +14.20pp |
| 2015-12-31 | 50.92% | $112.99 Million | $221.90 Million | -29.16pp |
| 2014-12-31 | 80.08% | $260.63 Million | $325.46 Million | -11.97pp |
| 2013-12-31 | 92.05% | $174.08 Million | $189.12 Million | +45.94pp |
| 2012-12-31 | 46.11% | $50.07 Million | $108.59 Million | -29.12pp |
| 2011-12-31 | 75.23% | $24.16 Million | $32.11 Million | -3.53pp |
| 2010-12-31 | 78.76% | $30.24 Million | $38.39 Million | +20.51pp |
| 2009-12-31 | 58.25% | $28.94 Million | $49.68 Million | -1.91pp |
| 2008-12-31 | 60.16% | $38.91 Million | $64.68 Million | -21.47pp |
| 2007-12-31 | 81.64% | $109.87 Million | $134.58 Million | +5.95pp |
| 2006-12-31 | 75.69% | $67.78 Million | $89.54 Million | +22.57pp |
| 2005-12-31 | 53.12% | $33.20 Million | $62.51 Million | -15.32pp |
| 2004-12-31 | 68.44% | $27.63 Million | $40.37 Million | +2.48pp |
| 2003-12-31 | 65.96% | $20.91 Million | $31.69 Million | +16.13pp |
| 2002-12-31 | 49.84% | $7.99 Million | $16.02 Million | -- |
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog … Read more